Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidayatullah

Showing results (251-260 of 262) with videos related to

Pageof 27
Sort By:
Research Square|July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|March 11, 2009
H5N1 surveillance in migratory birds in Java, IndonesiaArthur C Stoops, Katie A Barbara, Mochamad Indrawan, et al.
Nature Cardiovascular Research|November 11, 2025
Single-cell profiling reveals three endothelial-to-hematopoietic transitions with divergent isoform expression landscapesWen Hao Neo, Muhammad Zaki Hidayatullah Fadlullah, Harshangda Bhatnagar, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced MelanomaJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
BJC Reports|November 8, 2024
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of responseZoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, et al.
Journal for Immunotherapy of Cancer|May 12, 2025
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort studyZoe Quandt, Anastasia Lucas, Samantha I Liang, et al.
Nature Medicine|July 2, 2024
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNabil F Saba, Conor E Steuer, Asari Ekpenyong, et al.
Nature Medicine|April 3, 2023
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNabil F Saba, Conor E Steuer, Asari Ekpenyong, et al.
Oncotarget|April 7, 2016
Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapiesMuhammad Zaki Hidayatullah Fadlullah, Ivy Kim-Ni Chiang, Kalen R Dionne, et al.
Journal of Medicinal Chemistry|November 21, 2022
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for GlioblastomaLakshmi R Bollu, Prashant V Bommi, Paige J Monsen, et al.
Pageof 27

Showing results (251-260 of 262) with videos related to

Sort By:
Pageof 27
Research Square|July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|March 11, 2009
H5N1 surveillance in migratory birds in Java, IndonesiaArthur C Stoops, Katie A Barbara, Mochamad Indrawan, et al.
Nature Cardiovascular Research|November 11, 2025
Single-cell profiling reveals three endothelial-to-hematopoietic transitions with divergent isoform expression landscapesWen Hao Neo, Muhammad Zaki Hidayatullah Fadlullah, Harshangda Bhatnagar, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced MelanomaJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
BJC Reports|November 8, 2024
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of responseZoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, et al.
Journal for Immunotherapy of Cancer|May 12, 2025
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort studyZoe Quandt, Anastasia Lucas, Samantha I Liang, et al.
Nature Medicine|July 2, 2024
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNabil F Saba, Conor E Steuer, Asari Ekpenyong, et al.
Nature Medicine|April 3, 2023
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trialNabil F Saba, Conor E Steuer, Asari Ekpenyong, et al.
Oncotarget|April 7, 2016
Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapiesMuhammad Zaki Hidayatullah Fadlullah, Ivy Kim-Ni Chiang, Kalen R Dionne, et al.
Journal of Medicinal Chemistry|November 21, 2022
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for GlioblastomaLakshmi R Bollu, Prashant V Bommi, Paige J Monsen, et al.
Pageof 27